# Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

> **NCT00678652** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 36 (actual)

## Conditions studied

- Meningococcal Infection, Group B

## Interventions

- **BIOLOGICAL:** 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- **BIOLOGICAL:** 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- **BIOLOGICAL:** 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- **BIOLOGICAL:** 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine

## Key facts

- **NCT ID:** NCT00678652
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678652, "Phase 1 Safety and Immunogenicity of Meningococcal Vaccine". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00678652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*